Are Allergy Shots Worth It? A Pragmatic Cost-Benefit Framework

For most insured patients with moderate-to-severe allergies, allergy shots are financially worthwhile over a 5-10 year horizon. Hankin et al. (Ann Allergy Asthma Immunol 2010) found total 18-month healthcare costs were 33% lower for immunotherapy-treated patients versus matched controls — about $1,625 in savings, with cost reduction emerging within just 3 months of starting. A German Markov model (Bruggenjurgen et al. 2008) projects SCIT to be cost-saving at 10 years compared to ongoing symptomatic treatment, with a negative ICER meaning it saves money while improving health. However, the math assumes treatment completion — the 82% of patients who discontinue before 3 years (Hankin pediatric data) realize only a fraction of the modeled savings.

The most underestimated cost of allergy shots is time, not money. A conventional 3-5 year SCIT course requires approximately 85-90 clinic visits, each taking roughly 1.5-2 hours including travel and the mandatory 30-minute post-injection observation period — totaling 100-165 hours of patient time. Patients averaged 14 hours of missed work and 16 hours of reduced productivity per year in one pharmacoeconomic study (Pokladnikova et al., Ann Allergy Asthma Immunol 2008). For patients in rural areas or those without easy access to an allergist, travel time can double or triple these estimates. Additional hidden costs include deductible resets, annual vial renewal fees, and dose resets required after missed injections.

Yes, and for parents of allergic children this is often the most compelling ROI argument. The PAT study (Moller et al., JACI 2002; Jacobsen et al., Allergy 2007) found that SCIT in children with allergic rhinitis reduced asthma development with an odds ratio of 2.5 at 10 years, sustained 7 years after treatment ended. The number needed to treat is approximately 5-6 children treated to prevent one new asthma case. Given that childhood asthma carries lifetime medication costs, hospitalization risk, and quality-of-life burden, preventing even one asthma case dramatically improves the economic case for immunotherapy. Adults with existing asthma can also expect reduced medication use — the Abramson Cochrane review (2010) found an NNT of 3 to prevent one deterioration in asthma symptoms.

Benefits after a completed 3-5 year SCIT course typically persist 7-12 years — not just for the duration of treatment. The Durham NEJM 1999 trial showed sustained remission 3+ years post-discontinuation versus untreated controls. Eng et al. (Allergy 2006) found significant clinical benefit 12 years after stopping in pediatric patients. This post-treatment durability dramatically changes the worth-it calculation: instead of comparing treatment cost to a single year of medication savings, you should compare it against 7-12 years of reduced symptoms and medication use without ongoing immunotherapy. New sensitization prevention adds further long-term value — treated patients showed 23.75% vs. 68.03% polysensitization rates versus untreated controls (Purello-D'Ambrosio et al., 2001).

Allergy shots are least worth it for patients with mild, single-allergen seasonal symptoms that are fully controlled by inexpensive OTC antihistamines and nasal steroids. If a $15-20/month medication regimen adequately manages your symptoms, the 3-5 year commitment, 80+ clinic visits, and cumulative copays are difficult to justify purely on economic grounds. SCIT is also a poor investment for patients who are unlikely to complete the full course due to work schedules, lack of local allergist access, needle phobia, or frequent travel — since only patients who reach the 3-year minimum reliably achieve durable remission. The AAAAI recommends reassessing after one full year of maintenance dosing if no improvement is evident.

Yes — the time burden is often underestimated by patients before they start. A conventional buildup phase requires approximately 24-30 clinic visits in 3-6 months, typically weekly. Each visit involves travel time, check-in, the injection itself, and a 30-minute post-injection observation period. Over a full 5-year course, in-clinic patients typically make 85-90 total visits, translating to roughly 100-165 hours of patient time. At-home SCIT through Curex changes that math for eligible maintenance patients: the same allergy-shot immunotherapy is self-administered weekly at home, with the first injection and every dose change supervised live over Zoom and a brief self-observation per dose, eliminating the routine clinic trips and most of the travel hours. For working adults or parents, this distinction can determine whether any form of immunotherapy is feasible at all.

Yes — medication reduction is one of the most consistent benefits documented in SCIT research. The Calderon Cochrane review (2007) found a pooled medication score SMD of -0.57 across 51 trials, meaning patients on allergy shots used significantly less rescue medication than placebo. In practice, patients who complete the full course often eliminate or dramatically reduce daily antihistamine, nasal steroid, and decongestant use. Hankin's Medicaid analysis found that immunotherapy-treated patients incurred lower prescription costs, fewer physician visits, and fewer allergy-related hospitalizations compared to matched controls. The reduction in medication burden is a key component of the total cost savings and quality-of-life gains that define the worth-it calculation.